Cagrilintide

Synonyms: Cagrilintide, 1415456-99-3, Amylin analog, Long-acting amylin analog, NN-9935, Cagrilintide acetate

Cagrilintide is a synthetic analog of human amylin, a peptide hormone that works alongside insulin to regulate postprandial glucose levels and signal satiety. Developed by Novo Nordisk, this long-acting amylin analog is designed for once-weekly dosing, making it a promising candidate for obesity and type 2 diabetes management. Its extended half-life is achieved through fatty acid acylation, which promotes albumin binding and slows renal clearance.

Function

• Amylin receptor agonist: Activates amylin receptors, reducing food intake and delaying gastric emptying.
• Appetite regulation: Enhances satiety signaling, leading to reduced caloric intake.
• Weight management: Promotes weight loss in overweight and obese individuals.
• Glycemic control: Helps regulate postprandial glucose levels.

Source & Standardization

• Source: Synthetic peptide, produced via solid-phase peptide synthesis.
• Standardization: Purity ≥98% (HPLC), peptide content 70-90%.
• Forms: Lyophilized powder, acetate salt.
• Applications: Research on obesity, type 2 diabetes, and metabolic disorders.

Documentation & Supply

• MOQ: 5g
• Monthly capacity: 1 kg
• Lead time: 5-10 days after order
• Documentation: COA, MSDS, TDS
• Packaging: Sealed vials or custom packaging

Request For Quote

• Our Address: 280 Main Street, Xian, Shaanxi, China
• LyvBio Co., Ltd. — Email: info@lyvbio.com